EANS-Adhoc: Oxygen Biotherapeutics Names Dr. Ronald Blanck Chairman of the Board

--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------

01.10.2011

MORRISVILLE, NC, September 30, 2011— Oxygen Biotherapeutics, Inc.
(NASDAQ & SIX Swiss Exchange: OXBT) today announced that Ronald R.
Blanck, DO, was appointed Chairman of the Board of Directors of the
company.

The company also reported that in light of the shareholder vote
received today at the General Annual Meeting of Shareholders Rene A.
Eckert and J. Melville Engle resigned as directors of the company.
Neither of the resignations was the result of any disagreement with
the company or the Oxygen Board of Directors.

In a letter to the board, Mr. Engle said, "I respect the vote as an
indicator of desired change and am abiding thereto. I believe in the
company and I wish the best for our shareholders in the future."

In a separate letter to the board, Mr. Eckert said, "I wish to make
clear that my resignation is not due to any disagreement with the
company, its Board of Directors or its management, and each continues
to have my full support."

This board change brings the Oxygen Board of Directors to three
members. At this time, the company will evaluate the existing board
structure and future needs.

In an unrelated matter, the company also announced that Chief Medical
Officer Dr. Gerald Klein notified the company of his intent to resign
in October because he accepted a position with another company.

"We are sorry to see Dr. Klein, Mr. Eckert and Mr. Engle leave but we
understand and respect their decisions. We wish to thank them for
their service to our company. We highly value the insight they have
provided and appreciate their contributions," said Chief Financial
Officer and Interim Chief Executive Officer Michael Jebsen.

"We are pleased that Dr. Blanck has agreed to accept the chairmanship
of our board. His medical expertise and leadership abilities will be
invaluable to us as we navigate the clinical development of medical
products," Mr. Jebsen added.

end of ad-hoc-announcement ==========================================
====================================== About Ronald R. Blanck, DO

Dr. Blanck is chairman of Martin, Blanck & Associates, a federal
health services consulting firm. He completed a 32-year military
career as Lieutenant General and Surgeon General of the U.S. Army,
and commander of the U.S. Army Military Command. He also served as
commander of Walter Reed Medical Center and the North Atlantic Region
Medical Command. His background also includes serving as president of
the University of North Texas Health Science Center at Fort Worth.

About Oxygen Biotherapeutics, Inc.

Headquartered in Morrisville, NC, Oxygen Biotherapeutics, Inc. is
developing medical and cosmetic products that efficiently deliver
oxygen to tissues in the body. The company has developed a
proprietary perfluorocarbon (PFC) therapeutic oxygen carrier product
called Oxycyte® that is being formulated for both intravenous and
topical delivery. The company has commercialized its DERMACYTE® line
of oxygen-rich skin care products. In addition, the company is
focused on PFC-based oxygen carriers for use in traumatic brain
injury, decompression sickness, and topical wound healing. See
www.oxybiomed.com, or www.DermacyteUS.com for more information.

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by the
company that involve risks and uncertainties and reflect the
company’s judgment as of the date of this release. These statements
include the management transition, and expansion of research and
development of the Oxycyte product line, including the timing of the
introduction of these new products. The forward-looking statements
are subject to a number of risks and uncertainties including matters
beyond the company’s control that could lead to delays in new product
introductions and customer acceptance of these new products, and
other risks and uncertainties as described in our filings with the
Securities and Exchange Commission, including in the current annual
report on Form 10-K filed on July 15, 2011. The company disclaims any
intent or obligation to update these forward-looking statements
beyond the date of this release. This caution is made under the safe
harbor provisions of the Private Securities Litigation Reform Act of
1995.

Further inquiry note:
Ellen Corliss
Vice President, Corporate Communications
& Investor Relations
Oxygen Biotherapeutics, Inc
One Copley Pkwy, Suite 490
Morrisville, NC 27560
Direct Telephone: +1 919 855 2112
Direct Fax: +1 919 806 4417
Email: e.corliss@oxybiomed.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: Oxygen Biotherapeutics Inc.
One Copley Parkway, Suite 490
US-27560 Morrisville, NC
phone: +1 (919) 855 21 12
FAX: +1 (919) 806 44 17
mail: e.corliss@oxybiomed.com
WWW: www.oxybiomed.com
sector: Biotechnology
ISIN: US69207P2092
indexes: SSIRT
stockmarkets: Nasdaq: New York, Main Standard: SIX Swiss Exchange
language: English